News und Analysen
![Acadia Healthcare Reports Second Quarter 2020 Results](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Acadia Healthcare Reports Second Quarter 2020 Results
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced financial results for the second quarter ended June 30, 2020.
The Company reported revenue of $750.3 million for the second quarter
![Transgene Receives $22.2 Million from the Sale of Part of its Minority Stake in Tasly BioPharmaceuticals](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Transgene Receives $22.2 Million from the Sale of Part of its Minority Stake in Tasly BioPharmaceuticals
Regulatory News:
Transgene (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces that it has raised $22.2 million (€ 19
![Premier Inc. ProvideGx® Program Partners with Somerset Pharma to Stabilize Pricing, Enhance Competition for Sulfamethoxazole/Trimethoprim](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Premier Inc. ProvideGx® Program Partners with Somerset Pharma to Stabilize Pricing, Enhance Competition for Sulfamethoxazole/Trimethoprim
Premier Inc. (NASDAQ: PINC), through its ProvideGx® program, has partnered with Somerset Pharma, LLC., to supply sulfamethoxazole/trimethoprim, an antibiotic combination used to treat respiratory
![Sernova Enters into Exclusive Worldwide License Agreement with University of Miami for Therapeutic Cell Immune Protection Technologies](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Sernova Enters into Exclusive Worldwide License Agreement with University of Miami for Therapeutic Cell Immune Protection Technologies
Sernova expands its intellectual property portfolio and capabilities to develop first-in-class cell therapy solutions for type 1 diabetes and other chronic diseases that eliminate the need
![Sernova unterzeichnet weltweites exklusives Lizenzabkommen mit der University of Miami hinsichtlich therapeutischer Zell-Immunschutz-Technologien](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Sernova unterzeichnet weltweites exklusives Lizenzabkommen mit der University of Miami hinsichtlich therapeutischer Zell-Immunschutz-Technologien
Sernova erweitert sein Portfolio an geistigem Eigentum sowie seine Fähigkeiten hinsichtlich der Entwicklung erstklassiger Zelltherapie-Lösungen für Typ-1-Diabetes und andere chronische
![Simulations Plus Announces Proposed Underwritten Public Offering](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Simulations Plus Announces Proposed Underwritten Public Offering
Simulations Plus, Inc. (Nasdaq: SLP), a premier developer of drug discovery and development software for modeling and simulation software products and services for the pharmaceutical
![Antibe Therapeutics Provides Corporate Update](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Antibe Therapeutics Provides Corporate Update
Antibe Therapeutics Inc.:
- Phase II secondary data confirmed remarkable potency of ATB-346 -
- 3rd party commercial studies project peak annual sales of $5.3 billion across seven key countries
![Aurinia Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Aurinia Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that Peter Greenleaf, President and Chief Executive Officer of Aurinia, will participate in a fireside chat at
![Bayer: Diese Gewinnwarnung ist gar nicht das Problem!](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Bayer: Diese Gewinnwarnung ist gar nicht das Problem!
Der Leverkusener Chemie- und Pharmagigant Bayer (WKN: BAY001) legte heute früh seine aktuellen Quartalszahlen vor. Demnach wurde in Q2 ein Umsatz in Höhe von 10,05 Milliarden Euro bei einem EBIT von
![CO.DON AG: Erfolgreiche Hauptversammlung 2020](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
CO.DON AG: Erfolgreiche Hauptversammlung 2020
Berlin / Teltow / Leipzig, 04. August 2020 - Am 30. Juli 2020 fand in Berlin unter der Leitung des stellvertretenden Aufsichtsratsvorsitzenden Herrn Stählin die diesjährige Hauptversammlung
![Neutrisci Receives Final Approval from The Japanese Health Ministry](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Neutrisci Receives Final Approval from The Japanese Health Ministry
Vancouver, British Columbia – August 4, 2020 – NeutriSci International Inc. (“NeutriSci” or the “Company”) (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9), an innovative technology company
![NeutriSci erhält vom japanischen Gesundheitsministerium die finale Produktzulassung](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
NeutriSci erhält vom japanischen Gesundheitsministerium die finale Produktzulassung
Vancouver, British Columbia – 4. August 2020 – NeutriSci International Inc. („NeutriSci“ oder das „Unternehmen“) (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9), ein innovatives
![American Renal Associates Holdings, Inc. Announces Second Quarter 2020 Earnings Release Date and Conference Call](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
American Renal Associates Holdings, Inc. Announces Second Quarter 2020 Earnings Release Date and Conference Call
American Renal Associates Holdings, Inc. (NYSE: ARA), a leading kidney care and dialysis services provider focused on partnering with local nephrologists, announced today that it will release its
![IMV Inc. to Announce Second Quarter 2020 Results and Host a Conference Call and Webcast on August 12, 2020](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
IMV Inc. to Announce Second Quarter 2020 Results and Host a Conference Call and Webcast on August 12, 2020
IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines to fight against infectious
![NanoString Extends Leadership in Spatial Genomics with Launch of GeoMx DSP Read-Out for Next Generation Sequencers](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
NanoString Extends Leadership in Spatial Genomics with Launch of GeoMx DSP Read-Out for Next Generation Sequencers
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced the commercial availability of the first GeoMx®
![Trevena vor FDA-Entscheidung: +331% nach NBC-Empfehlung!](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Trevena vor FDA-Entscheidung: +331% nach NBC-Empfehlung!
Woche der Wahrheit für Trevena (WKN: A1XDSL): Die US-Gesundheitsbehörde wird bis Freitag über die Zulassung des Schmerzmittels Oliceridine entscheiden.
Bis 2,89 USD geht es für die Trevena-Aktie
![MEDICREA Announces the Appointment of an Independent Expert](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
MEDICREA Announces the Appointment of an Independent Expert
The MEDICREA® Group (Euronext Growth Paris: FR0004178572 – ALMED ; OTCQX Best Market –MRNTF), pioneering the transformation of spinal surgery through Artificial Intelligence, predictive modeling
![Xencor Earns Milestone Payment from MorphoSys for FDA Approval of Monjuvi® (tafasitamab-cxix) in the United States](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Xencor Earns Milestone Payment from MorphoSys for FDA Approval of Monjuvi® (tafasitamab-cxix) in the United States
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, announced that the U.S. Food
![Quidel Receives Preliminary Contract Leading to Definitive Agreement for $71 Million Under NIH’s RADx-ATP Program to Accelerate the Expansion of Its Manufacturing Capacity for Sofia® SARS-CoV-2 Antigen Detection Test for Rapid Diagnosis of COVID-19](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Quidel Receives Preliminary Contract Leading to Definitive Agreement for $71 Million Under NIH’s RADx-ATP Program to Accelerate the Expansion of Its Manufacturing Capacity for Sofia® SARS-CoV-2 Antigen Detection Test for Rapid Diagnosis of COVID-19
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has
![Pfizer and BioNTech to Supply Japan with 120 Million Doses of their BNT162 mRNA-based Vaccine Candidate](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Pfizer and BioNTech to Supply Japan with 120 Million Doses of their BNT162 mRNA-based Vaccine Candidate
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced an agreement with the Ministry of Health, Labour and Welfare (MHLW) in Japan to supply 120 million doses of BNT162 mRNA-based
![Quidel Reports Second Quarter 2020 Financial Results](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Quidel Reports Second Quarter 2020 Financial Results
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the
![First EOSedgeTM installation in the United States](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
First EOSedgeTM installation in the United States
EOS imaging (Euronext, FR0011191766 - EOSI - PEA-PME eligible), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and surgical planning, today announces
![BASF, Colgate-Palmolive, Estée Lauder, and Unilever Among Keynote Speakers at 2020 Veeva Quality & Regulatory Global Summit](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
BASF, Colgate-Palmolive, Estée Lauder, and Unilever Among Keynote Speakers at 2020 Veeva Quality & Regulatory Global Summit
Veeva Systems (NYSE: VEEV) today announced the featured keynote speakers at 2020 Veeva Quality & Regulatory Global Summit. Leaders from the world’s top consumer goods, chemical, and cosmetics
![Premier Healthcare Database Being Used by National Institutes of Health to Evaluate Impact of COVID-19 on Patients Across the U.S.](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Premier Healthcare Database Being Used by National Institutes of Health to Evaluate Impact of COVID-19 on Patients Across the U.S.
Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, today announced a data licensing agreement with the National Institutes of Health (NIH). Under the terms of the agreement
![Savara to Report Second Quarter 2020 Financial Results and Provide Business Update](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Savara to Report Second Quarter 2020 Financial Results and Provide Business Update
Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced that the Company will report second quarter 2020 financial results and provide a business update on Thursday, August 6